A need for further investigation for fluorescence image-guided surgery in breast conserving
surgery (BCS) has arisen following the results obtained from a phase I feasibility breast
cancer trial (BIRDYE study: ABR NL 37479.042011). The aim of this study is to define the
optimal dose of the fluorescent tracer Bevacizumab-IRDye800CW for intraoperative delineation
of breast cancer tissue using the improved and optimized fluorescent tracer and camera
system.